ArticleEClinicalMedicine2025
Utility of disease probability scores to guide decision-making during screening for phaeochromocytoma and paraganglioma: a machine learning modelling cross sectional study.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pheochromocytomas and Paragangliomas.Endocrinology and metabolism clinics of North America · 2026Review
- Artificial Intelligence and Machine Learning in Pediatric Endocrine Tumors: Opportunities, Pitfalls, and a Roadmap for Trustworthy Clinical Translation.Biomedicines · 2026Review
- Robustness of steroidomics-based machine learning for diagnosis of primary aldosteronism: a laboratory medicine perspective.Clinical chemistry and laboratory medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interpretation of plasma metanephrines and methoxytyramine to assess likelihood of phaeochromocytoma/paraganglioma (PPGL) during screening can be challenging. This study (study period: 2021-2023) introduces new methods to select machine-learning (ML) models and evaluate derived probability-scores to better interpret laboratory results. Methods: ML models were trained and internally tested using data from 2046 patients with and without PPGL and according to several features: age, pre-test risk of PPGL, plasma metanephrines and methoxytyramine. External validation involved a second cohort of 1641 patients with and without PPGL. The study employed several processes to select and evaluate the best model: concordance of models with human intelligence; intra- and inter-laboratory variability in derived probability-scores; and comparison of scores of the selected model to predictions of ten clinical care specialists before and after provision of those scores. Findings: External validation established equally excellent diagnostic performance for all five best ML models according to areas under ROC curves (0.988-0.994) and balanced accuracies (0.958-0.981). Probability-scores of models, however, varied widely and were poorly correlated. The additional selection processes indicated an artificial-network model as a superior and more robust model than others. Predictions of disease likelihood by specialists, according to six categories from disease highly unlikely to disease clear, varied widely for individual patients. Within each of the six predictive categories, median probability-scores of the artificial-network model were 70-, 175-, 59-, 15-, 3.5- and 1.7-fold higher (P < 0.0001) in patients with than without PPGL. This superiority of probability scores over variable predictions by specialists remained evident after specialists were tasked to modify their predictions according to those scores. Interpretation: This study employed several novel processes to establish an ML model with probability-scores superior to predictions of disease likelihood by specialists. However, the negligible improvement in interpretations by specialists after provision of probability-scores indicates this alone is insufficient to improve decision-making. Funding: Deutsche Forschungsgemeinschaft.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.